BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Patel PM, Jones VA, Kridin K, Amber KT. The role of Dipeptidyl Peptidase-4 in cutaneous disease. Exp Dermatol 2021;30:304-18. [PMID: 33131073 DOI: 10.1111/exd.14228] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Solimani F, Didona D, Li J, Bao L, Patel PM, Gasparini G, Kridin K, Cozzani E, Hertl M, Amber KT. Characterizing the proteome of bullous pemphigoid blister fluid utilizing tandem mass tag labeling coupled with LC-MS/MS. Arch Dermatol Res 2021. [PMID: 34152480 DOI: 10.1007/s00403-021-02253-8] [Reference Citation Analysis]
2 Huang X, Khoong Y, Han C, Su D, Ma H, Gu S, Li Q, Zan T. Targeting Dermal Fibroblast Subtypes in Antifibrotic Therapy: Surface Marker as a Cellular Identity or a Functional Entity? Front Physiol 2021;12:694605. [PMID: 34335301 DOI: 10.3389/fphys.2021.694605] [Reference Citation Analysis]
3 Bao L, Li J, Perez White BE, Patel PM, Amber KT. Inhibition of dipeptidyl-peptidase 4 induces upregulation of the late cornified envelope cluster in keratinocytes. Arch Dermatol Res 2021. [PMID: 34089377 DOI: 10.1007/s00403-021-02249-4] [Reference Citation Analysis]
4 Nieto-Benito LM, Bergón-Sendín M, Pulido-Pérez A, Suárez-Fernández RM. Clinical outcome and safety profile of rituximab for the treatment of Dipeptidyl peptidase 4 inhibitors-induced Bullous pemphigoid. Exp Dermatol 2021. [PMID: 34695279 DOI: 10.1111/exd.14483] [Reference Citation Analysis]
5 Quaglino P, Novelli M, Fava P, Ortolan E, Astrua C, Tonella L, Tomasini CF, Senetta R, Ribero S, Ponti R, Fierro MT, Funaro A, Nicolazzo C. CD38 Expression by Circulating and Skin-Infiltrating Lymphocytes from Sezary Syndrome Patients: A Flow Cytometry and Immunohistochemistry Study. Disease Markers 2022;2022:1-7. [DOI: 10.1155/2022/3424413] [Reference Citation Analysis]